$5.15
6.19% today
Nasdaq, Apr 03, 06:46 pm CET
ISIN
US71722W1071
Symbol
PHAT
Sector
Industry

Phathom Pharmaceuticals Inc Stock price

$5.49
+0.28 5.37% 1M
-11.27 67.24% 6M
-2.63 32.39% YTD
-4.31 43.98% 1Y
-9.50 63.38% 3Y
-22.93 80.68% 5Y
-19.11 77.68% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.37 7.23%
ISIN
US71722W1071
Symbol
PHAT
Sector
Industry

Key metrics

Market capitalization $382.31m
Enterprise Value $640.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.58
P/S ratio (TTM) P/S ratio 6.92
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 8,001.47%
Revenue (TTM) Revenue $55.25m
EBIT (operating result TTM) EBIT $-277.47m
Free Cash Flow (TTM) Free Cash Flow $-266.91m
Cash position $297.26m
EPS (TTM) EPS $-5.35
P/E forward negative
P/S forward 2.34
EV/Sales forward 3.91
Short interest 28.88%
Show more

Is Phathom Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Phathom Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

Buy
88%
Hold
13%

Financial data from Phathom Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
55 55
8,025% 8,025%
100%
- Direct Costs 7.97 7.97
977% 977%
14%
47 47
78,900% 78,900%
86%
- Selling and Administrative Expenses 290 290
148% 148%
525%
- Research and Development Expense 34 34
32% 32%
62%
-277 -277
66% 66%
-501%
- Depreciation and Amortization 0.80 0.80
38% 38%
1%
EBIT (Operating Income) EBIT -277 -277
66% 66%
-502%
Net Profit -334 -334
66% 66%
-605%

In millions USD.

Don't miss a Thing! We will send you all news about Phathom Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Phathom Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
about 5 hours ago
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025,...
Neutral
GlobeNewsWire
2 days ago
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Steven Basta as President and Chief Executive Officer, the Company's Board of Directors has approved the grant of...
Neutral
GlobeNewsWire
2 days ago
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds ...
More Phathom Pharmaceuticals Inc News

Company Profile

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Head office United States
CEO Steven Basta
Employees 427
Founded 2018
Website www.phathompharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today